| Dr Ted Harold Fromm, MD | |
|
240 Minnesota St, Rapid City, SD 57701-6200 | |
| (605) 718-5123 | |
| Not Available |
| Full Name | Dr Ted Harold Fromm |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 240 Minnesota St, Rapid City, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043419914 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 5720 (Nebraska) | Secondary |
| 207W00000X | Ophthalmology | 7858 (South Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ted Harold Fromm, MD 405 N Berry Pine Rd, Rapid City, SD 57702-1856 Ph: (402) 547-8773 | Dr Ted Harold Fromm, MD 240 Minnesota St, Rapid City, SD 57701-6200 Ph: (605) 718-5123 |
News Archive
True 2 Beauty Inc., a leading distributor of male and female sexual potency pills and liquid products in the United States, is pleased to announce the launch of a new, additional line of sexual enhancement supplements for men and women under the brand Blue Diamond and Pink Diamond.
Heraeus Kulzer, LLC, the worldwide leader in dental esthetics, announced today that its iBOND Self Etch bonding agent received the maximum possible "5-plus" rating from THE DENTAL ADVISOR. The iBOND Self Etch bottle kit was evaluated by 26 consultants in 648 uses and received a very impressive 96% clinical rating.
Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca.
A team of prominent researchers led by Charles Sawyers, M.D. and Moshe Talpaz, M.D., presented compelling clinical findings today showing that a new drug, BMS-354825, can successfully treat patients who have become resistant to Gleevec (the frontline therapy for chronic myelogenous leukemia, CML).
The radiation of a cell phone base station at a distance of 80 metres causes significant changes of the electrical currents in the brains of testees (measured by electroencefalogram, EEG). All the testees said they felt unwell during the radiation, some of them seriously.
› Verified 8 days ago
Scott Eccarius, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 631 Saint Anne St, Suite 103, Rapid City, SD 57701 Phone: 605-343-4120 | |
Dr. Daniel J Hafner, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2800 3rd St, Rapid City, SD 57701 Phone: 605-341-2000 Fax: 605-719-3211 | |
Dr. Prema Abraham, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2800 3rd St, Rapid City, SD 57701 Phone: 605-341-2000 Fax: 605-719-3211 | |
Dr. Paul Louis Wright, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 240 Minnesota St, Rapid City, SD 57701 Phone: 605-718-5123 Fax: 605-719-9509 | |
Rebecca Linquist, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2820 Mount Rushmore Rd, Rapid City, SD 57701 Phone: 605-342-3280 Fax: 605-721-8458 | |
Robert B Nixon, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2800 3rd St, Rapid City, SD 57701 Phone: 605-341-2000 Fax: 605-719-3211 |